Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PSTX market cap is 913.25M. The company's latest EPS is USD -1.2664 and P/E is -2.26.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.01M | 9.35M | 25M | 28.14M | 25.97M |
| Operating Income | -27.86M | -36.22M | -25.91M | -24.58M | -31.76M |
| Net Income | -27.46M | -31.78M | -25.35M | -24.27M | -31.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 31.24M | 130.49M | 64.7M |
| Operating Income | -85.53M | -126.55M | -141.41M | -59.95M | -129.5M |
| Net Income | -86.53M | -129.78M | -124.97M | -64M | -123.43M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 281.22M | 302.25M | 273.89M | 262.58M | 298.69M |
| Total Liabilities | 145.91M | 178.59M | 170.18M | 177.99M | 237.87M |
| Total Equity | 135.3M | 123.66M | 103.7M | 84.59M | 60.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 147M | 371.48M | 269.31M | 351.84M | 273.89M |
| Total Liabilities | 74.33M | 109.52M | 113.1M | 164.24M | 170.18M |
| Total Equity | -149.51M | 261.97M | 156.21M | 187.6M | 103.7M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -71.31M | -63.42M | -92.17M | -15.14M | 23.32M |
| Investing | 38.66M | -8.58M | 39.13M | 24M | -37.2M |
| Financing | 1.19M | 16.13M | 16.13M | -43k | -43k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -64.39M | -113.33M | -102.54M | -26.77M | -92.17M |
| Investing | -42.59M | -204.43M | 222.38M | -203.33M | 39.13M |
| Financing | 164.37M | 313.94M | 2.52M | 105.16M | 16.13M |
| Market Cap | 913.25M |
| Price to Earnings Ratio | -2.26 |
| Price to Sales Ratio | 4.31 |
| Price to Cash Ratio | 6.27 |
| Price to Book Ratio | 2.69 |
| Dividend Yield | - |
| Shares Outstanding | 97.47M |
| Average Volume (1 week) | 336.11k |
| Average Volume (1 Month) | 545.51k |
| 52 Week Change | 234.64% |
| 52 Week High | 9.90 |
| 52 Week Low | 1.91 |
| Spread (Intraday) | 0.01 (0.11%) |
| Company Name | Poseida Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.poseida.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
